Sunitinib: Multi-Targeted RTK Inhibitor for Cancer Therap...
2025-10-21
Sunitinib’s multi-targeted receptor tyrosine kinase inhibition is revolutionizing anti-angiogenic cancer therapy workflows, especially in models of renal cell carcinoma and nasopharyngeal carcinoma. With potent, nanomolar-range activity and proven synergy in ATRX-deficient glioma research, Sunitinib enables precise dissection of RTK signaling and apoptosis induction in preclinical settings.